Literature DB >> 11519289

Anti-herpes viruses agents.

N M Abdel-Haq1, B I Asmar.   

Abstract

Antiviral agents with demonstrated efficacy are currently available for the management of infections in children caused by the herpes viruses including herpes simples type 1 (HSV1) and type 2 (HSV2), varicella-zoster virus (VZV), and cytomegalovirus (CMV). Recently, progress has been made in the development of newer agents with enhanced activity against these viruses including resistant strains. This review focuses on the activity, clinical pharmacology, and clinical indications of antiviral agents used in the treatment of infections caused by the different herpes viruses in children.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11519289     DOI： 10.1007/BF02752280

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   5.319


  35 in total

1.  Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204).

Authors:  W R Bell; J D Chulay; J E Feinberg
Journal:  Medicine (Baltimore)       Date:  1997-09       Impact factor: 1.889

Review 2.  Ganciclovir--a review of pharmacology, therapeutic efficacy and potential use for treatment of congenital cytomegalovirus infections.

Authors:  P Fan-Havard; M C Nahata; M T Brady
Journal:  J Clin Pharm Ther       Date:  1989-10       Impact factor: 2.512

Review 3.  Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.

Authors:  K C Cundy
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

4.  [Treatment of superficial herpes simplex keratitis with vidarabine (Vira A): multicenter study of 100 cases].

Authors:  J Denis; P Chouraqui; I Karpouzas; T Hoang-Xuan; Y Pouliquen
Journal:  J Fr Ophtalmol       Date:  1990       Impact factor: 0.818

Review 5.  Antisense oligonucleotides as therapeutic agents.

Authors:  U Galderisi; A Cascino; A Giordano
Journal:  J Cell Physiol       Date:  1999-11       Impact factor: 6.384

6.  Foscarnet nephrotoxicity: mechanism, incidence and prevention.

Authors:  G Deray; F Martinez; C Katlama; B Levaltier; H Beaufils; M Danis; M Rozenheim; A Baumelou; E Dohin; M Gentilini
Journal:  Am J Nephrol       Date:  1989       Impact factor: 3.754

7.  Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. Acyclovir Study Group.

Authors:  L H Goldberg; R Kaufman; T O Kurtz; M A Conant; L J Eron; R L Batenhorst; G S Boone
Journal:  Arch Dermatol       Date:  1993-05

8.  Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.

Authors:  R R MacGregor; A L Graziani; R Weiss; J E Grunwald; J G Gambertoglio
Journal:  J Infect Dis       Date:  1991-10       Impact factor: 5.226

Review 9.  Delirium associated with acyclovir treatment in a patient with renal failure.

Authors:  S G Revankar; A L Applegate; D M Markovitz
Journal:  Clin Infect Dis       Date:  1995-08       Impact factor: 9.079

10.  Acyclovir halts progression of herpes zoster in immunocompromised patients.

Authors:  H H Balfour; B Bean; O L Laskin; R F Ambinder; J D Meyers; J C Wade; J A Zaia; D Aeppli; L E Kirk; A C Segreti; R E Keeney
Journal:  N Engl J Med       Date:  1983-06-16       Impact factor: 91.245
View more
  1 in total

Review 1.  Bioactive activities of natural products against herpesvirus infection.

Authors:  Myoungki Son; Minjung Lee; Gi-Ho Sung; Taeho Lee; Yu Su Shin; Hyosun Cho; Paul M Lieberman; Hyojeung Kang
Journal:  J Microbiol       Date:  2013-10-31       Impact factor: 3.422
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.